CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Holds Robust IP Portfolio Protecting DehydraTECH Technology
Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) drug delivery platform DehydraTECH employs its patented technology to improve bio-absorption and bioavailability of active ingredients while covering unpleasant tastes. A recent article discussing the company’s technology reads, “Lexaria’s disruptive DehydraTECH drug delivery platform is protected by a robust suite of patents granted or pending worldwide. It has been proven effective in multiple international studies in greatly assisting rapidity and quantity of absorption of a range of lipophilic (i.e., fat-soluble), bioactive molecules – such as those contained in cannabinoids (CBD), nicotine, non-steroidal anti-inflammatory drugs (NSAIDs) and other molecules. DehydraTECH offers a healthier, oral ingestion…